First report of molecular detection of fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium tuberculosis isolates in Kuwait

BMC Research Notes

Eiman Mokaddas¹  Suhail Ahmad¹  Noura M Al-Mutairi¹ 

[1] Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait

关键词: Kuwait;    gyrA mutations;    Fluoroquinolone resistance;    M. tuberculosis;   

Others  :  1167567
DOI  :  10.1186/1756-0500-4-123

 received in 2010-12-17, accepted in 2011-04-14,  发布年份 2011

【 摘 要 】

Background

Nearly 5% of all Mycobacterium tuberculosis strains worldwide are resistant at least to rifampicin and isoniazid (multidrug-resistant tuberculosis, MDR-TB). Inclusion of a fluoroquinolone and an injectable agent (kanamycin, amikacin or capreomycin) in multidrug therapy is crucial for proper treatment of MDR-TB. The incidence of MDR-TB in Kuwait is ~1%. MDR-TB strains additionally resistant to fluoroquinolones and injectable agents are defined as extensively drug-resistant (XDR-TB) strains and have been detected in >55 countries. Infections with XDR-TB strains have very poor prognosis. This study detected the occurrence of gyrA mutations associated with fluoroquinolone resistance among MDR-TB strains in Kuwait.

Findings

Direct DNA sequencing of quinolone resistance-determining region of gyrA gene was performed to detect fluoroquinolone resistance-associated mutations in 85 MDR-TB strains isolated from 55 TB patients and 25 pansusceptible M. tuberculosis strains. For isolates exhibiting gyrA mutations, 3'-end of rrs (16S rRNA) was sequenced for the detection of XDR-TB. Fingerprinting of fluoroquinolone resistant MDR-TB strains was performed by detecting mutations in three (81 bp hot-spot, N-terminal and cluster II) regions of rpoB, katG codon 315 and inhA-regulatory region, polymorphisms at gyrA codon 95 and katG codon 463 by DNA sequencing and by double-repetitive-element PCR for determining strain relatedness. None of the pansusceptible but six of 85 MDR-TB strains contained gyrA mutations. Only gyrA codon 94 was mutated in all six (D94A in one and D94G in five) strains. Three of six mutant strains were recovered from the same patient while three other strains represented individual patient isolates. Fingerprinting studies identified all individual patient isolates as epidemiologically distinct strains. All six strains with a gyrA mutation contained wild-type rrs sequence.

Conclusions

Although fluoroquinolones are generally not used for chemotherapy of TB and drug susceptibility testing for second-line drugs is not carried out in Kuwait, four of 55 (7%) individual patient MDR-TB strains contained mutations in gyrA gene. The data advocate routine drug susceptibility testing for this important second-line drug for proper management of MDR-TB in Kuwait. Lack of mutations in 3'-end of rrs gene that confer resistance to injectable agents reduce the likelihood of occurrence of XDR-TB, at present, in Kuwait.

【 授权许可】

   
2011 Ahmad et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: Global tuberculosis control: WHO report 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO; 2010.
• [2]World Health Organization: Anti-tuberculosis drug resistance in the world: fourth Global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO; 2008.
• [3]Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M, for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Epidemiology of antituberculosis drug resistance 2002-2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009, 373:1861-1873.
• [4]Ahmad S, Mokaddas E: Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Resp Med 2009, 103:1777-1790.
• [5]World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO; 2010.
• [6]Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W: Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007, 4:article no. e292.
• [7]Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
• [8]Ahmad S, Mokaddas E: New challenges in the treatment of tuberculosis in the 21st century. Treat Strat Resp 2011, 1:100-110.
• [9]Mitnick CD, Shin SS, Seung GY, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC: Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359:563-574.
• [10]Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB: Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51:6-14.
• [11]Gandhi NR, Moll A, Sturn AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1554-1556.
• [12]Kliman K, Altraja A: Predictors of poor treatment outcome in multi and extensively drug-resistant pulmonary TB. Eur Respir J 2009, 33:1085-1094.
• [13]American Thoracic Society, CDC, Infectious Disease Society of America: Treatment of tuberculosis. Morb Mort Weekly Rep 2003, 52:1-77.
• [14]Ginsburg AS, Grosset JH, Bishai WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
• [15]Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC: Fluoroquinolones resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
• [16]Chang KC, Yew WW, Chan RCY: Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010, 65:1551-1561.
• [17]Hillemann D, Rusch-Gerdes S, Richter E: Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009, 47:1767-1772.
• [18]Maus CE, Pilkaytis BB, Shinnick TM: Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:3192-3197.
• [19]Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L: High level cross-resistance between kanamycin, amikacin and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009, 53:5064-5068.
• [20]Mokaddas E, Ahmad S, Samir I: Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008, 12:319-325.
• [21]Mokaddas E, Ahmad S: Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jpn J Infect Dis 2007, 60:140-144.
• [22]Jaber AA, Ahmad S, Mokaddas E: Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Ann Clin Microbiol Antimicrob 2009, 8:2. BioMed Central Full Text
• [23]Ahmad S, Mokaddas E, Jaber AA: Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes 2004, 18:299-306.
• [24]Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM: Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997, 94:9869-9874.
• [25]Al-Mutairi N, Ahmad S, Mokaddas E: Performance comparison of four methods for rapid detection of multidrug-resistant Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis 2011, 15:110-115.
• [26]Ahmad S, Jaber AA, Mokaddas E: Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007, 87:123-129.
• [27]Mokaddas E, Ahmad S, Abal AT: Molecular fingerprinting of isoniazid-resistant Mycobacterium tuberculosis isolates from Chest Diseases Hospital in Kuwait. Microbiol Immunol 2002, 46:767-771.
• [28]Behbehani N, Abal A, Al-Shami A, Enarson DA: Epidemiology of tuberculosis in Kuwait from 1965 to 1999. Int J Tuberc Lung Dis 2002, 6:465-469.
• [29]Mokaddas E, Ahmad S: Species spectrum of nontuberculous mycobacteria isolated from clinical specimens in Kuwait. Curr Microbiol 2008, 56:413-417.
• [30]Ahmad S: New approaches in the diagnosis and treatment of latent tuberculosis infection. Resp Res 2010, 11:169. BioMed Central Full Text
• [31]Ahmad S, Mokaddas E, Fares E: Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis 2002, 44:245-252.
• [32]Ahmad S, Mokaddas E: The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 2005, 26:205-212.
• [33]Van Soolingen D: Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001, 249:1-26.
• [34]Shi R, Zhang J, Li C, Kazumi Y, Sugawara I: Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006, 44:4566-4568.
• [35]Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, Rastogi N: Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008, 52:2937-2939.
• [36]van Doorn HR, An DD, de Jong MD, Lan NTN, Hoa DV, Quy HT, Chau NVV, Duy PM, Tho DQ, Chinh NT, Farrar JJ, Caws M: Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 2008, 12:736-742.
• [37]Ando H, Mitarai S, Kondo Y, Suetake T, Kato S, Mori T, Kirikae T: Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol 2011, 60:184-188.
• [38]Giannoni F, Iona E, Sementilli F, Brunori L, Pardini M, Migliori GB, Orefici G, Fattorini L: Evaluation of a line probe assay for the rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:2928-2933.